Sign Up to like & get
recommendations!
1
Published in 2017 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-16-0886
Abstract: Exploratory clinical trials using therapeutic anti-HER3 antibodies strongly suggest that neuregulin (NRG1; HER3 ligand) expression at tumor sites is a predictive biomarker of anti-HER3 antibody efficacy in cancer. We hypothesized that in NRG1-expressing tumors, where…
read more here.
Keywords:
anti her3;
her3 antibody;
9f7 f11;
binding her3 ... See more keywords